Alzheimer’s
Heptares announces positive early-stage dementia trial results
February 10, 2016Research and Development Alzheimer's, Alzheimers, Heptares, dementia, schizophrenia
Heptares has announced positive findings from its Phase 1b clinical study with its investigational drug HTL9936 as a treatment for …
Alzheimer’s drugs prescriptions rise six-fold in a decade
January 19, 2016Manufacturing and Production Alzheimer's, Alzheimer's disease, NHSIC, dementia, prescribing
The number of prescriptions dispensed in England for approved medicines to treat Alzheimer’s increased from 502,000 in 2004 to 3 …
The case for adaptive trials in dementia
January 6, 2016Manufacturing and Production, Research and Development Alzheimer's, Alzheimer's disease, adaptive trials, research
An ageing population and widespread chronic neuro-degenerative disease will make dementia an ever increasing burden on society, families and the …
Lilly, Biogen and Roche debut Alzheimer’s disease drug results
July 22, 2015Research and Development Alzheimer's, Alzheimer's disease, Biogen, Conference, Eli Lilly, Roche, lilly
Big pharma companies have posted mixed results in trials of several potential new treatments for Alzheimer’s disease. But the results, …
AbbVie invests $30 million to expand in Puerto Rico
March 23, 2015Manufacturing and Production, Sales and Marketing AbbVie, Alzheimer's, Puerto Rico, barceloneta, c2n
AbbVie is investing $30 million to expand one of its sites in Puerto Rico, and is also backing a promising …
Biogen shortens name and posts positive Alzheimer’s results
March 23, 2015Sales and Marketing AD, Alzheimer's, BIIB037, Biogen, MS, Parkinson's, aducanumab, idec
Biogen Idec is to be known only as Biogen hence forth as the US biotech also reveals positive early results …
Big pharma partners with government over $100m dementia fund
March 17, 2015Research and Development, Sales and Marketing Alzheimer's, Biogen IDEC, GSK, J&J, JJ, Pfizer, government, jp morgan, lilly
Lilly, Pfizer, GSK, J&J and Biogen Idec are set to join a $100m Dementia Discovery Fund to boost research into …
Eisai Alzheimer’s drug to see China review
March 4, 2015Sales and Marketing Alzheimer's, Aricept, China, Eisai, donepezil hydrochloride
Alzheimer’s drug Aricept from Eisai has been accepted for review in China to treat patients with the most severe form …
Roche dealt with two late-stage blows
December 19, 2014Sales and Marketing Alzheimer's, Alzheimer’s, Cancer, Kadcyla, Perjeta, Roche, Xeloda, trastuzumab emtansine
Swiss giant Roche’s breast cancer treatment Kadcyla has failed to meet its primary endpoint and its investigational Alzheimer’s treatment trial …
Otsuka buys Avanir for $3.5 billion
December 3, 2014Sales and Marketing Abilify, Alzheimer's, Alzheimer’s, Nuedexta, Otsuka, Parkinson's, Parkinson’s, avanir
Otsuka is to buy Avanir Pharmaceuticals for $3.5 billion as it looks to make up for the imminent patent expiry …
AZ and Lilly Alzheimer’s drug enters trials
December 1, 2014Research and Development, Sales and Marketing AZD3293, Alzheimer's, AstraZeneca, LY3314814, lilly
AstraZeneca and Eli Lilly have begun a Phase II/II trial for their Alzheimer’s treatment AZD3293 as the companies hope to …
Mayor of London calls for dementia R&D centre
October 8, 2014Research and Development, Sales and Marketing Alzheimer's, Boris Johnson, London, dementia, research
The mayor of London Boris Johnson is calling on both the government and the private sector to come together and …
AstraZeneca teams up with rival Lilly for Alzheimer’s
September 16, 2014Research and Development, Sales and Marketing AZD3293, Alzheimer's, Alzheimer’s, AstraZeneca, BACE, lilly
AstraZeneca and US rival Lilly have signed an agreement to develop a new and experimental pill for the treatment of …
Dementia diagnoses on the rise
July 30, 2014Medical Communications, Research and Development, Sales and Marketing Alzheimer's, david cameron, dementia
The number of patients in England diagnosed with dementia has increased by 62% over seven years according to provisional figures …
Mixed bag for Genentech dementia drug
July 18, 2014Research and Development, Sales and Marketing Alzheimer's, Genentech, crenezumab, dementia
A Phase II clinical trial for Genentech’s investigational Alzheimer’s drug failed to meet its primary endpoints – but the company …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
